BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 20109602)

  • 1. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anderson-Fabry disease.
    Di Toro A; Favalli V; Arbustini E
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
    [No Abstract]   [Full Text] [Related]  

  • 4. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
    Morrissey RP; Philip KJ; Schwarz ER
    Cardiovasc J Afr; 2011; 22(1):38-44. PubMed ID: 21298206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: A fundamental genetic modifier of cardiac function.
    Tadevosyan A
    Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heart involvement in Anderson-Fabry disease: Italian recommendations for diagnostic, follow-up and therapeutic management].
    Pieruzzi F; Pieroni M; Zachara E; Marziliano N; Morrone A; Cecchi F
    G Ital Cardiol (Rome); 2015 Nov; 16(11):630-8. PubMed ID: 26571477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fabry-Anderson disease: current state of knowledge].
    Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
    Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac manifestation of Fabry's disease: current knowledge].
    Palecek T; Lubanda JC; Magage S; Karetová D; Bultas J; Linhart A
    Vnitr Lek; 2004 Nov; 50(11):846-51. PubMed ID: 15648965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.